FDA Expedites Review of Becker’s Disorder Treatment
- The Food and Drug Governance (FDA) has accepted a resubmission of the New Drug Request (NDA) for elamipretide, developed by Stealth BioTherapeutics, as a potential treatment for barth...
- The resubmission, filed on August 15, 2024, seeks accelerated approval based on promising Phase 2 trial data.
- This acceptance follows a previous rejection by the FDA in may 2024, with the agency providing no specific reasons for the initial decision.
FDA Accepts Resubmission for Elamipretide, Potential Breakthrough for Barth Syndrome
The Food and Drug Governance (FDA) has accepted a resubmission of the New Drug Request (NDA) for elamipretide, developed by Stealth BioTherapeutics, as a potential treatment for barth syndrome. This rare genetic disorder, affecting approximately 150 people in the United States, can lead too severe heart failure and muscle weakness.
Accelerated Approval Pathway
The resubmission, filed on August 15, 2024, seeks accelerated approval based on promising Phase 2 trial data. Results demonstrated a greater than 45% enhancement in muscle strength among participants. If approved, elamipretide would represent a notable advancement in treating this currently underserved patient population. A postmarketing trial will be required to further confirm the drug’s clinical benefits.
Previous Setback and Expedited Review
This acceptance follows a previous rejection by the FDA in may 2024, with the agency providing no specific reasons for the initial decision. Despite this setback, the FDA has assigned a target review date of September 26, 2024 – substantially ahead of the standard February 15, 2025, deadline. This expedited review suggests the agency recognizes the urgent need for effective therapies for Barth syndrome.
The advancement of elamipretide has spanned decades, and this resubmission represents a critical step toward potentially providing a life-changing treatment option for individuals living with Barth syndrome.